IMR Press / FBE / Volume 3 / Issue 1 / DOI: 10.2741/E214

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Biomarker discovery and identification from non-small cell lung cancer sera
Show Less
1 Department of Respiratory Medicine, Second Affiliated Hospital of Medical School, Xi’an Jiaotong University, Xi’an, China
2 Second Hospital of Xi’an, Xi’an, China
3 Department of General Thoracic Surgery, Second Affiliated Hospital of Medical School, Xi’an Jiaotong University, Xi’an, China

*Author to whom correspondence should be addressed.

Academic Editor: Xueji Zhang

Front. Biosci. (Elite Ed) 2011, 3(1), 1–10;
Published: 1 January 2011
(This article belongs to the Special Issue Biosensors and their applications)

Currently, serum biomarkers might usually be thought not to be used for early detection of lung cancer by some researchers. In this study, we used a highly optimized ClinProt-matrix-assisted laser desorption/ionization time-of flight mass spectrometer (MALDI-TOF-MS) to screen non-small cell lung carcinoma (NSCLC) markers in serum. A training set of spectra derived from 45 NSCLC patients, 24 patients with benign lung diseases (BLDs) and 21 healthy individuals, was used to develop a proteomic pattern that discriminated cancer from non-cancer effectively. A test set, including 74 cases (29 NSCLC patients and 45 controls), was used to validate this pattern. After cross-validation, the classifier showed sensitivity and specificity, 86.20% and 80.00%, respectively. Remarkably, 100% of early stage serum samples could be correctly classified as lung cancer. Furthermore, the differential peptides of 1865Da and 4209Da were identified as element of component 3 and eukaryotic peptide chain release factor GTP-binding subunit ERF, respectively. The patterns we described and peptides we identified may have clinical utility as surrogate markers for detection and classification of NSCLC.

Back to top